• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Calise Chris bought $10,879 worth of shares (11,582 units at $0.94), increasing direct ownership by 0.80% to 1,464,897 units

    8/31/23 4:01:06 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BHSE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Calise Chris

    (Last) (First) (Middle)
    105 BRADFORD ROAD, SUITE 420

    (Street)
    WEXFORD PA 15090

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Coeptis Therapeutics Holdings, Inc. [ COEP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/23/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/23/2023 P 9,000 A $0.94 1,462,315(1) D
    Common Stock 08/23/2023 P 2,582 A $0.9367 1,464,897(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Includes (i) 942,117 shares of common stock that are issuable under currently exercisable options and (ii) 7,500 shares of common stock that are issuable upon exercise of options that will become exercisable. Does not include 22,500 shares of common stock that are issuable upon exercise of options that are not currently exercisable and will not become exercisable in the next 60 days.
    /s/ Christopher Calise 08/31/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BHSE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHSE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BHSE
    SEC Filings

    View All

    SEC Form 424B3 filed by Bull Horn Holdings Corp.

    424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/5/24 5:17:01 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Bull Horn Holdings Corp.

    424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/5/24 5:15:23 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bull Horn Holdings Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    2/1/24 5:28:10 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:03:11 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Cogley Brian claimed ownership of 30,000 shares (SEC Form 3)

    3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:01:21 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/16/24 8:14:38 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp.

    Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol "COEP" WEXFORD, Pa. and MIAMI, Oct. 31, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. ("Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings Corp. (NASDAQ:BHSE), a special purpose acquisition company ("Bull Horn").  In connection with the Business Combination, the combined company has been renamed "Coeptis Therapeutics Holdings, Inc." (the "Company") and its public shares and warrants are expected to commence trading on the Nasdaq G

    10/31/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology

    SNAP-CAR therapy provides a highly programmable therapeutic platform designed to potentially target many tumor types, including hematological malignancies and solid tumors WEXFORD, Pa., Sept. 21, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer.

    9/21/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors

    Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial

    5/17/22 7:00:00 AM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/17/24 4:03:11 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/16/24 8:14:38 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Yerace Daniel Alexander bought $7,486 worth of shares (10,850 units at $0.69), increasing direct ownership by 1% to 1,071,455 units (SEC Form 4)

    4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

    1/9/24 5:32:29 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BHSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bull Horn Holdings Corp.

    SC 13G - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    2/14/24 3:32:56 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Bull Horn Holdings Corp. (Amendment)

    SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    2/6/23 4:25:12 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Bull Horn Holdings Corp.

    SC 13D - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    11/7/22 4:10:32 PM ET
    $BHSE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care